FUMAPMS
Dimethyl fumarate treatment of primary progressive multiple sclerosis
What was tested
Treatment tested
- Dimethyl fumarate
Kelch-like ECH-associated protein 1 inhibitor
What it measured
Main measures
The primary aim of the study is to assess whether 48 weeks of treatment with dimethyl fumarate can decrease neuroaxonal damage in PPMS as assessed by:
Other measures (1)
• Clinical endpoints: comparison of change from screening to week 48 in patients treated with dimethyl fumarate and placebo for the following variables:
Loading reviews and guidelines…
Related trials
- STOP-I-SEP
Phase 3 · Running, not recruiting
Still running
- FUMAPMS
Phase 2 · Completed
Missed its main goal
- Pharmacokinetics of DMF and the Effects of DMF on Explora…
Phase 4 · Completed
No result found
History
- In scope changed from true to false
Started
Jun 2016
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error